SRDX - Surmodics Non-GAAP EPS of -$0.50 beats by $0.16 revenue of $24.9M beats by $0.93M

• Surmodics press release ( NASDAQ: SRDX ): Q1 Non-GAAP EPS of -$0.50 beats by $0.16 .
• Revenue of $24.9M (+8.3% Y/Y) beats by $0.93M .
• Fiscal Year 2023 Financial Guidance
• Surmodics now expects fiscal year 2023 total revenue to range from $102 million to $106 million vs $104.84M consensus, representing an increase of 2% to 6% compared to the prior year. The Company’s prior guidance called for fiscal year 2023 total revenue to range from $103 million to $107 million, representing an increase of 3% to 7% compared to the prior year.
• The Company now expects fiscal 2023 GAAP diluted loss per share to range from $(2.40) to $(2.00). The Company’s prior guidance called for fiscal 2023 GAAP diluted loss per share to range from $(2.80) to $(2.40).
• Non-GAAP diluted loss per share in fiscal 2023 is expected to range from $(2.09) to $(1.69) vs -$2.38 consensus. The Company’s prior guidance called for fiscal 2023 Non-GAAP diluted loss per share in fiscal 2023 to range from $(2.54) to $(2.14).

For further details see: